Importance of Expedited FDA Approval Process of Infigratinib for Treatment of Locally Advanced or Metastatic Cholangiocarcinoma

Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the importance of the FDA’s expedited approval process for infigratinib in the treatment of previously treated locally advanced or metastatic cholangiocarcinoma.

Pharmacy Times interviewed Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, on the phase 2 trial results that led to the US FDA approval of infigratinib (Truseltiq, QED Therapeutics) for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

During this discussion, Javle addressed the importance of the US FDA’s expedited approval process for infigratinib in the treatment of previously treated locally advanced or metastatic cholangiocarcinoma.